IL241354D0 - Bisecific fc molecules, compositions comprising same, methods of producing same and uses thereof - Google Patents

Bisecific fc molecules, compositions comprising same, methods of producing same and uses thereof

Info

Publication number
IL241354D0
IL241354D0 IL241354A IL24135415A IL241354D0 IL 241354 D0 IL241354 D0 IL 241354D0 IL 241354 A IL241354 A IL 241354A IL 24135415 A IL24135415 A IL 24135415A IL 241354 D0 IL241354 D0 IL 241354D0
Authority
IL
Israel
Prior art keywords
same
bisecific
molecules
compositions
methods
Prior art date
Application number
IL241354A
Other languages
Hebrew (he)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361791424P priority Critical
Priority to PCT/US2014/029253 priority patent/WO2014144722A2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL241354D0 publication Critical patent/IL241354D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
IL241354A 2013-03-15 2015-09-09 Bisecific fc molecules, compositions comprising same, methods of producing same and uses thereof IL241354D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201361791424P true 2013-03-15 2013-03-15
PCT/US2014/029253 WO2014144722A2 (en) 2013-03-15 2014-03-14 BISPECIFIC-Fc MOLECULES

Publications (1)

Publication Number Publication Date
IL241354D0 true IL241354D0 (en) 2015-11-30

Family

ID=50489434

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241354A IL241354D0 (en) 2013-03-15 2015-09-09 Bisecific fc molecules, compositions comprising same, methods of producing same and uses thereof

Country Status (21)

Country Link
US (4) US20140302037A1 (en)
EP (1) EP2970477A2 (en)
JP (2) JP6535654B2 (en)
KR (1) KR20150139531A (en)
CN (1) CN105229031A (en)
AP (1) AP201508773A0 (en)
AU (1) AU2014228829B2 (en)
BR (1) BR112015023431A2 (en)
CA (1) CA2902961A1 (en)
CL (1) CL2015002756A1 (en)
CR (1) CR20150573A (en)
EA (1) EA201591814A1 (en)
HK (1) HK1214275A1 (en)
IL (1) IL241354D0 (en)
MA (1) MA38400A1 (en)
MX (1) MX2015012187A (en)
PE (1) PE20151998A1 (en)
PH (1) PH12015502083A1 (en)
SG (1) SG11201506647SA (en)
TN (1) TN2015000379A1 (en)
WO (1) WO2014144722A2 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302665B (en) * 2011-12-21 2019-04-23 安姆根有限公司 And the variant Fc polypeptide of the combination enhancing of neonatal Fc receptor
BR112015000798A2 (en) * 2012-07-13 2017-06-27 Zymeworks Inc Bispecific asymmetric heterodimers comprising anti-cd3 constructs
EP3424952A1 (en) * 2013-03-15 2019-01-09 Amgen, Inc Heterodimeric bispecific antibodies
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CR20160314A (en) 2013-12-17 2016-08-29 Genentech Inc Anti-CD3 antibodies and methods of use
US20170247476A1 (en) * 2014-09-25 2017-08-31 Amgen Inc. Protease-activatable bispecific proteins
RU2017121327A3 (en) 2014-11-20 2019-05-28
JP2018510623A (en) * 2015-02-20 2018-04-19 オハイオ・ステイト・イノベーション・ファウンデーション Bivalent antibodies against NKG2D and tumor-associated antigens
WO2017011414A1 (en) * 2015-07-10 2017-01-19 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
WO2017011413A1 (en) * 2015-07-10 2017-01-19 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
MX2017013348A (en) 2015-04-17 2018-08-01 Amgen Res Munich Gmbh Bispecific antibody constructs for cdh3 and cd3.
US20180125972A1 (en) * 2015-05-13 2018-05-10 Chugai Seiyaku Kabushiki Kaisha Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
CN111234027A (en) 2015-05-21 2020-06-05 哈普恩治疗公司 Trispecific binding proteins and methods of use
TW201706307A (en) 2015-07-31 2017-02-16 安美基研究(慕尼黑)公司 Antibody constructs for CD70 and CD3
TW201708257A (en) 2015-07-31 2017-03-01 安美基研究(慕尼黑)公司 Antibody constructs for FLT3 and CD3
TW201708256A (en) 2015-07-31 2017-03-01 安美基研究(慕尼黑)公司 Antibody constructs for MSLN and CD3
TW201716441A (en) 2015-07-31 2017-05-16 安美基研究(慕尼黑)公司 Antibody constructs for EGFRVIII and CD3
TW201708261A (en) 2015-07-31 2017-03-01 安美基研究(慕尼黑)公司 Antibody constructs for DLL3 and CD3
TW201718002A (en) 2015-08-05 2017-06-01 安美基研究(慕尼黑)公司 Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers
KR20180038045A (en) * 2015-08-17 2018-04-13 마크로제닉스, 인크. A bispecific monovalent diabody capable of binding to B7-H3 and CD3, and its use
KR20180073561A (en) * 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 Double specific anti-CEAXCD3 T cell activating antigen binding molecules
AR106199A1 (en) * 2015-10-02 2017-12-20 F Hoffmann-La Roche Ag Antigen binding molecules bispecific activating cells t
CN107207608A (en) * 2015-10-30 2017-09-26 江苏众红生物工程创药研究院有限公司 Bispecific antibody, preparation method and use
MX2018008347A (en) 2016-01-08 2018-12-06 Hoffmann La Roche Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies.
MX2018009386A (en) 2016-02-03 2018-11-09 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs.
JP2017186301A (en) 2016-02-03 2017-10-12 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Bcma and cd3 bispecific t cell engaging antibody constructs
US20170368169A1 (en) 2016-03-21 2017-12-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
BR112018016281A2 (en) * 2016-03-22 2019-01-02 Hoffmann La Roche protease activatable bispecific t-cell activating molecule, idiotype-specific polypeptide, pharmaceutical composition, uses of the bispecific molecule and method of treating a disease in an individual
SG11201808656SA (en) 2016-04-19 2018-10-30 Amgen Res Munich Gmbh Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
BR112018073761A2 (en) 2016-05-20 2019-02-26 Harpoon Therapeutics Inc binding proteins CD3 single chain variable fragment
WO2018018011A2 (en) 2016-07-22 2018-01-25 Amgen Inc. Methods of purifying fc-containing proteins
CN110198737A (en) 2016-11-23 2019-09-03 哈普恩治疗公司 Target the tri-specific protein and application method of PSMA
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
JP2020506924A (en) 2017-02-02 2020-03-05 アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング Low pH pharmaceutical compositions containing T cell engage antibody constructs
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
MX2019013142A (en) 2017-05-05 2019-12-16 Amgen Inc Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration.
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
BR112019023856A2 (en) 2017-05-12 2020-06-09 Harpoon Therapeutics Inc triespecific proteins targeting msln and methods of use
JP2020522254A (en) 2017-05-31 2020-07-30 エルスター セラピューティクス, インコーポレイテッド Multispecific molecules that bind myeloproliferative leukemia (MPL) proteins and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
KR20200096814A (en) 2017-12-11 2020-08-13 암젠 인크 Continuous manufacturing process of bispecific antibody product
TW201940518A (en) 2017-12-29 2019-10-16 美商安進公司 Bispecific antibody construct directed to MUC17 and CD3
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US20200002425A1 (en) * 2018-03-26 2020-01-02 Altor Bioscience Corporation Anti-pdl1, il-15 and tgf-beta receptor combination molecules
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TW202021616A (en) 2018-07-30 2020-06-16 美商安進公司 Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
WO2020025596A1 (en) 2018-07-31 2020-02-06 Amgen Research (Munich) Gmbh Dosing regimen for bcma-cd3 bispecific antibodies
TW202023611A (en) 2018-08-03 2020-07-01 德商安美基研究(慕尼黑)公司 Antibody constructs for cldn18.2 and cd3
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
TW202028239A (en) 2018-09-28 2020-08-01 美商安進公司 Antibodies against soluble bcma
WO2020077212A1 (en) 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2020086635A1 (en) 2018-10-23 2020-04-30 Amgen Inc. Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions
WO2020159838A1 (en) 2019-01-28 2020-08-06 Amgen Inc. A continuous manufacturing process for biologics manufacturing by integration of drug substance and drug product processes
WO2020172596A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
WO2020172601A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020172598A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68913658T3 (en) 1988-11-11 2005-07-21 Medical Research Council Cloning of immunoglobulin sequences from the variable domains
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
CA2326389C (en) * 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1355919E (en) 2000-12-12 2011-03-02 Medimmune Llc Molecules with extended half-lives, compositions and uses thereof
CN1195779C (en) * 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 Double-specificity antibody resisting human ovary cancer and human CD3
BR0316282A (en) * 2002-11-15 2005-10-11 Genmab As Isolated human antibody, hybridoma, transfectoma, eukaryotic or prokaryotic host cell, non-human animal or transgenic plant, method for producing a human monoclonal antibody, composition, immunoconjugate, bispecific or multispecific molecule, method for inhibiting the development and / or proliferation of a cd25 expressing cell, method for eliminating a cd25 expressing cell, method for treating or preventing a disorder involving cd25 expressing cells, method and diagnostic kit for detecting the presence of cd25 antigen or a cd25 expressing cell, vector of expression, anti-idiotic antibody, and use of it
CA2522586C (en) * 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AR056142A1 (en) 2005-10-21 2007-09-19 Amgen Inc Methods for generating monovalent IgG antibody
AU2008234020B2 (en) * 2007-04-03 2013-02-07 Amgen Research (Munich) Gmbh Cross-species-specific CD3-epsilon binding domain
MX2009010611A (en) * 2007-04-03 2010-03-26 Micromet Ag Cross-species-specific bispecific binders.
CN103694350B (en) * 2007-04-03 2018-04-24 安进研发(慕尼黑)股份有限公司 Cross-species-specific cd 3-epsilon binding domain
US20090155275A1 (en) * 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
BRPI0820270A2 (en) * 2007-11-07 2015-06-16 Celldex Therapeutics Inc Monoclonal antibody, expression vector, cell, molecular conjugate, composition, use of composition, method for detecting the presence or absence of dec-205 in a biological sample, and use of a molecular conjugate.
CN108864285A (en) * 2008-01-03 2018-11-23 斯克里普斯研究院 Pass through the antibody target of modular recognition domain
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2010321720B2 (en) * 2009-11-23 2017-03-02 Amgen Inc. Monomeric antibody Fc
CN102939303A (en) * 2009-12-22 2013-02-20 诺瓦提斯公司 Tetravalent cd47-antibody constant region fusion protein for use in therapy
MX340437B (en) * 2010-02-24 2016-07-08 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof.
AU2012245116A1 (en) * 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
TWI588156B (en) * 2011-03-28 2017-06-21 賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
ME03025B (en) * 2011-04-01 2018-10-20 Immunogen Inc Methods for increasing efficacy of folr1 cancer therapy
US20130078250A1 (en) * 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
AU2012323287B2 (en) * 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
ES2749349T3 (en) * 2011-11-07 2020-03-19 Medimmune Llc Multispecific and multivalent binding proteins and uses thereof
CN104302665B (en) 2011-12-21 2019-04-23 安姆根有限公司 And the variant Fc polypeptide of the combination enhancing of neonatal Fc receptor
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES

Also Published As

Publication number Publication date
BR112015023431A2 (en) 2017-11-28
PE20151998A1 (en) 2016-02-03
MX2015012187A (en) 2016-04-15
AU2014228829B2 (en) 2019-01-17
CA2902961A1 (en) 2014-09-18
CN105229031A (en) 2016-01-06
JP6535654B2 (en) 2019-06-26
JP2019151634A (en) 2019-09-12
AU2014228829A1 (en) 2015-09-10
US20180230220A1 (en) 2018-08-16
SG11201506647SA (en) 2015-09-29
US20190002568A1 (en) 2019-01-03
TN2015000379A1 (en) 2017-01-03
AP201508773A0 (en) 2015-09-30
US20140302037A1 (en) 2014-10-09
EA201591814A1 (en) 2016-03-31
CR20150573A (en) 2015-11-19
HK1214275A1 (en) 2016-07-22
WO2014144722A2 (en) 2014-09-18
EP2970477A2 (en) 2016-01-20
WO2014144722A3 (en) 2014-11-06
KR20150139531A (en) 2015-12-11
MA38400A1 (en) 2017-09-29
US20160145340A1 (en) 2016-05-26
JP2016516056A (en) 2016-06-02
CL2015002756A1 (en) 2016-04-15
PH12015502083A1 (en) 2016-01-18

Similar Documents

Publication Publication Date Title
IL255682A (en) Seed-origin endophyte populations, compositions, and methods of use
IL273205D0 (en) Compositions and methods
HK1220480A1 (en) Engineered liver tissues, arrays thereof, and methods of making the same
HK1218648A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
HK1218837A1 (en) Compositions and methods
HK1218560A1 (en) Compositions and methods
IL244081D0 (en) Compositions and methods for modulating rna
HRP20170888T1 (en) Tubulysin compounds, methods of making and use
IL244254D0 (en) Engineered anti-dll3 conjugates and methods of use
HK1220222A1 (en) Benzylisoquinoline alkaloids (bia) producing microbes, and methods of making and using the same (bia)
HK1223913A1 (en) Substituted benzamides and methods of use thereof
ZA201506682B (en) Compositions and methods for the improved production and delivery of rna
GB2535360B (en) Methods of preparing polyhemiaminals and polyhexahydrotriazines
EP3076967A4 (en) Novel methods
EP3080289A4 (en) Modified nucleic acid molecules and uses thereof
ZA201601524B (en) Production of graphene and graphane
HK1214275A1 (en) Bispecific-fc molecules fc
HK1213930A1 (en) Sulfone-containing polythioethers, compositions thereof, and methods of synthesis
ZA201406671B (en) Multispecific antigen-binding molecules and uses thereof
IL274355D0 (en) Aza-pyridone compounds and uses thereof
IL243752D0 (en) Multispecific antibodies, compositions comprising same and uses thereof
EP2994518A4 (en) Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
IL250925A (en) Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto
JP2015529698A5 (en) Compositions comprising nanostructures and methods for producing nanostructures
EP3065875A4 (en) Bioprinter and methods of using same